Report says less favorable Pradaxa data withheld from FDA

| | Cardiovascular Business | Heart Rhythm

Bloomberg News reported that Boehringer Ingelheim provided the FDA with one analysis showing a lower rate of fatal bleeding events in patients treated with dabigatran (Pradaxa) than was found in a second analysis that the company chose not to share.

The drug maker disclosed earlier that it faces more than 2,000 lawsuits in the U.S. from patients or their families over safety issues related to the anticoagulant. 

Boehringer kept Pradaxa analysis from FDA, records show

Related Content

FDA announces recall of cryoablation catheters after multiple injuries, including 4 deaths
Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker
President of medical device company resigns over conduct allegations after 7 months in role
FDA and Boston Scientific issue urgent alert about pacemaker failures following 2 deaths
Treating AFib patients with TAVR still linked to elevated risks
Cardiologists work to standardize the diagnosis and management of acute myocarditis

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.